Cameron McDonough
Chief Executive Officer at GENERATION BIO CO.
Net worth: 5 M $ as of 30/04/2024
Cameron McDonough active positions
Companies | Position | Start | End |
---|---|---|---|
GENERATION BIO CO. | Director/Board Member | 01/10/2017 | - |
Chief Executive Officer | 01/10/2017 | - | |
President | 01/10/2017 | - | |
THIRD HARMONIC BIO, INC. | Director/Board Member | 28/03/2024 | - |
Independent Dir/Board Member | 28/03/2024 | - | |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - | - |
Career history of Cameron McDonough
Former positions of Cameron McDonough
Companies | Position | Start | End |
---|---|---|---|
SURFACE ONCOLOGY, INC. | Director/Board Member | 22/02/2018 | 28/02/2022 |
Independent Dir/Board Member | 22/02/2018 | 28/02/2022 | |
PTC THERAPEUTICS, INC. | Director/Board Member | 06/11/2012 | 18/09/2017 |
Independent Dir/Board Member | 06/11/2012 | 18/09/2017 | |
SWEDISH ORPHAN BIOVITRUM AB | Chief Executive Officer | 15/08/2011 | 22/05/2017 |
President | 15/08/2011 | 22/05/2017 | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2002 | - |
Catalyst Medical Solutions, Inc. | Founder | - | - |
President | - | - | |
LARIMAR THERAPEUTICS, INC. | Director/Board Member | 28/09/2015 | - |
Independent Dir/Board Member | 28/09/2015 | - |
Training of Cameron McDonough
Harvard Medical School | Graduate Degree |
The University of North Carolina at Chapel Hill | Undergraduate Degree |
Statistics
International
United States | 11 |
Sweden | 2 |
Operational
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
President | 3 |
Sectoral
Health Technology | 8 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
PTC THERAPEUTICS, INC. | Health Technology |
GENERATION BIO CO. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
Private companies | 5 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Catalyst Medical Solutions, Inc. | |
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
- Stock Market
- Insiders
- Cameron McDonough
- Experience